Physician profile
Robert Gnade
NPI 1659301281
$1,814.47
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,586 · 2020: $228.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $338.60 | 2019-2020 | |
| Amgen INC. | $332.90 | 2019-2020 | |
| Allergan, INC. | $212.74 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.89 | 2019 | |
| Janssen Pharmaceuticals, INC | $158.73 | 2019 | |
| Lilly USA, LLC | $156.12 | 2019 | |
| Abbvie INC. | $82.38 | 2019 | |
| Amarin Pharma, INC. | $62.69 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $59.44 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $48.76 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $24.26 | 2019 | |
| Novo Nordisk INC | $23.58 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.52 | 2019 | |
| Astellas Pharma US INC | $15.10 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.16 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $12.46 | 2019 | |
| Pfizer INC. | $11.49 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.35 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.00 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gnade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.